AtriCure
AtriCure specializes in medical devices for atrial fibrillation and related conditions, offering innovative solutions like the Isolator® Synergy™ Ablation System and AtriClip® devices, with a global presence and a strong focus on clinical science and education.
Services
AtriCure primarily offers a range of medical devices designed for the treatment of atrial fibrillation and related cardiac conditions. The company focuses on providing innovative solutions, such as its unique technologies in ablation systems, left atrial appendage management, and minimally invasive therapies. Additional services include investing in clinical science, innovation, and education to improve patient outcomes across various regions globally.
Products
AtriCure's product portfolio includes the Isolator® Synergy™ Ablation System, which is the first FDA-approved device for treating persistent atrial fibrillation (Afib). The AtriClip® Left Atrial Appendage Exclusion System is another key product, recognized as the most widely sold LAA management device in the world. Their Hybrid AF™ Therapy offers a minimally invasive solution for long-standing persistent Afib. The cryoICE cryoSPHERE® probe is used for the temporary ablation of peripheral nerves, helping to manage postoperative pain in cardiac and thoracic procedures. AtriCure’s products are available in approximately 60 countries worldwide.
Headquarters and Global Presence
AtriCure is headquartered near Cincinnati, Ohio. The company also has significant operations in Minneapolis, Minnesota, and Amsterdam, Netherlands. AtriCure's products are distributed and sold in approximately 60 countries, demonstrating its strong international presence. With a robust workforce including over 1,200 employees and 450 scientists and engineers, AtriCure is equipped to meet the diverse needs of healthcare practitioners globally.
Patents and Innovations
AtriCure holds 220 issued patents in the USA, highlighting its commitment to innovation in the medical device industry. The company's substantial investment in research and development is evident through its development of pioneering products such as the FDA-approved Isolator® Synergy™ Ablation System. AtriCure's emphasis on innovation is also reflected in the continuous enhancement of its product lines and contributions to clinical science and medical education.
Employee Strength
AtriCure employs over 1,200 individuals worldwide, including more than 450 scientists and engineers. This diverse and skilled workforce plays a critical role in the company's efforts to innovate and advance the field of cardiac medical devices. The combined expertise of AtriCure's employees ensures the ongoing development of effective and groundbreaking technology for the treatment of atrial fibrillation and associated conditions.